Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review

Authors: Aaron Conway, Alexandra L McCarthy, Petra Lawrence, Robyn A Clark

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

The benefits associated with some cancer treatments do not come without risk. A serious side effect of some common cancer treatments is cardiotoxicity. Increased recognition of the public health implications of cancer treatment-induced cardiotoxicity has resulted in a proliferation of systematic reviews in this field to guide practice. Quality appraisal of these reviews is likely to limit the influence of biased conclusions from systematic reviews that have used poor methodology related to clinical decision-making. The aim of this meta-review is to appraise and synthesise evidence from only high quality systematic reviews focused on the prevention, detection or management of cancer treatment-induced cardiotoxicity.

Methods

Using Cochrane methodology, we searched databases, citations and hand-searched bibliographies. Two reviewers independently appraised reviews and extracted findings. A total of 18 high quality systematic reviews were subsequently analysed, 67 % (n = 12) of these comprised meta-analyses.

Results

One systematic review concluded that there is insufficient evidence regarding the utility of cardiac biomarkers for the detection of cardiotoxicity. The following strategies might reduce the risk of cardiotoxicity: 1) The concomitant administration of dexrazoxane with anthracylines; 2) The avoidance of anthracyclines where possible; 3) The continuous administration of anthracyclines (>6 h) rather than bolus dosing; and 4) The administration of anthracycline derivatives such as epirubicin or liposomal-encapsulated doxorubicin instead of doxorubicin. In terms of management, one review focused on medical interventions for treating anthracycline-induced cardiotoxicity during or after treatment of childhood cancer. Neither intervention (enalapril and phosphocreatine) was associated with statistically significant improvement in ejection fraction or mortality.

Conclusion

This review highlights the lack of high level evidence to guide clinical decision-making with respect to the detection and management of cancer treatment-associated cardiotoxicity. There is more evidence with respect to the prevention of this adverse effect of cancer treatment. This evidence, however, only applies to anthracycline-based chemotherapy in a predominantly adult population. There is no high-level evidence to guide clinical decision-making regarding the prevention, detection or management of radiation-induced cardiotoxicity.
Appendix
Available only for authorised users
Literature
1.
Stratigos A, Forsea A, Van Der Leest R, et al. Euromelanoma: a dermatology‐led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 2012;167:99–104.CrossRefPubMed
2.
3.
Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7:935–43.CrossRefPubMed
4.
Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10:351–69.CrossRefPubMed
5.
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMed
6.
Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16:3–10.CrossRefPubMed
7.
Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37:300–11.CrossRefPubMed
8.
Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23:vii155–vii66.CrossRefPubMed
9.
Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org
10.
11.
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084–96.CrossRefPubMed
12.
Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2010;55:213–20.CrossRefPubMed
13.
Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis. 2010;53:140–8.CrossRefPubMed
14.
Chargari C, Kirov KM, Bollet MA, et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev. 2011;37:321–30.CrossRefPubMed
15.
Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015;66:161–76.CrossRefPubMed
16.
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.CrossRefPubMedPubMedCentral
17.
Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. J Am Med Assoc. 2006;295:1281–7.CrossRef
18.
19.
Collaboration TC. Cochrane handbook for systematic reviews of interventions version 5.1. 2011. Available from www.cochrane-handbook.org
20.
Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013–20.CrossRefPubMed
21.
Qin Y-Y, Li H, Guo X-J, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30,698 patients. PLoS One. 2011;6:e26946.CrossRefPubMedPubMedCentral
22.
Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007, Issue 4 Art No. CD004421.
23.
Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.CrossRefPubMedPubMedCentral
24.
Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer. 2013;133:2245–52.CrossRefPubMed
25.
Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast. 2012;21:343–9.CrossRefPubMed
26.
Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J. Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004, Issue 4. Art No. CD003367
27.
Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006, Issue 4. Art No. CD005247
28.
Van Dalen E, Raphaël M, Caron H, Kremer L. Treatment including anthracyclines versus treatment not in-cluding anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2011, Issue 1 Art. No.: CD006647
29.
van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011, Issue 6 Art No. CD003917
30.
van Dalen EC, Michiels E, Caron HN, Kremer L. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010, Issue 5. Art No. CD005006
31.
van Dalen EC, Van der Pal H, Caron HN, Kremer L. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009, Issue 4. Art No. CD005008
32.
Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.CrossRefPubMedPubMedCentral
33.
Itchaki G, Gafter Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M. Anthracycline containing regimens for treatment of follicular lymphoma in adults. Cochrane Database Syst Rev. 2013, Issue 7. Art. No. CD008909.
34.
Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol. 2004;22:4418–24.CrossRefPubMed
35.
Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer. 2007;96:226–30.CrossRefPubMedPubMedCentral
36.
Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer. 2007;43:1959–66.CrossRefPubMed
37.
Sieswerda E, Kremer L, Caron H, van Dalen E. The use of liposomal anthracycline analogues for childhood malignancies: a systematic review. Eur J Cancer. 2011;47:2000–8.CrossRefPubMed
38.
Sieswerda E, van Dalen EC, Postma A, Cheuk D, Caron HN, Kremer L. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Systematic Reviews. 2011; Issue 9: CD008011.
39.
van Dalen EC, Caron HN, Kremer L. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer. 2007;43:1134–40.CrossRefPubMed
40.
Chan R. Two decades of exceptional achievements: does the evidence support nurses to favour Cochrane systematic reviews over other systematic reviews? Int J Nurs Stud. 2012;49:773–4.CrossRefPubMed
41.
Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer current evidence and underlying mechanisms. Circulation. 2011;124:642–50.CrossRefPubMedPubMedCentral
Metadata
Title
The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review
Authors
Aaron Conway
Alexandra L McCarthy
Petra Lawrence
Robyn A Clark
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1407-6

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients

Research article

Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?

Research article

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression

Research article

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

Retraction Note

Retraction Note: STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells

Research article

HGUE-C-1 is an atypical and novel colon carcinoma cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits